A survey of the quality of generic clarithromycin products from 18 countries

Clinical Drug Investigation

Volumn 25, Issue 2, 2005, Pages 135-152

  Nightingale, C H ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,11 O DIMETHYLERYTHROMYCIN A; ADEL; BERAFEN; BICROLID; BINOCLAR; CLACIN; CLAMONT; CLARION; CLARIPEN; CLARITEK; CLARITHRO; CLARITHRO 250; CLARITHROMYCIN; CLARITROMICIN A; CLARITROMICINA ALTER; CLARITROMICINA BEXAL; CLARITROMICINA GEMINIS; CLARITROMICINA KERN; CLAROMYCIN; CLAROS; CLARYTAS; CLERON; CRIXAN; E CLAR; ERYTHROMYCIN; EZUMYCIN; FROMILID; GENERIC DRUG; HAMMI; ISET; KLARI; KLARIBACT; KLARICARE; KLERIMED; NEO KLAR; PATHOCIN; ULCECURE; UNCLASSIFIED DRUG;

AFRICA; ARTICLE; ASIA; DRUG APPROVAL; DRUG DETERMINATION; DRUG FORMULATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG PURITY; DRUG QUALITY; DRUG SOLUBILITY; EUROPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; TABLET;

EID: 14644444179     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525020-00006     Document Type: Article

References (18)

1. Langtry HD, Brigadoon RN. Clarithromycin: a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973-1004
2. Peters DH, Clissold SJ. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-64
3. McCarty JM. Clarithromycin in the management of community-acquired pneumonia. Clin Ther 2000; 22 (3): 281-94
4. Bogossian M. Use of clarithromycin for respiratory infections in general practice. Rev Bras Med 1995; 52: 500-9
5. Farhat CK. Use of Clarithromycin in respiratory infections in pediatrics. Mod Pediatr 1995; 31: 1-8
6. Endo LH. The use of Clarithromycin in respiratory infections in general practice. Otorrinolaringologia 1995; 2: 1-8
7. Lerner FE, Caliendo G, Santagada V, et al. Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. Int J Clin Pharmacol Ther 2000; 38 (7): 345-54
8. Lohitnavy M, Lohitnavy O, Wittaya-areekul S, et al. Average bioequivalence of clarithromycin immediate released tablet formulations in healthy male volunteers. Drug Dev Ind Pharm 2003; 29 (6): 653-9
9. Lohitnavy O, Lohitnavy M, Sareekan K, et al. Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers. Biopharm Drug Dispos 2003; 24 (6): 229-31
10. Nightingale CH. A survey of the quality of generic clarithromycin products from 13 countries. Clin Drug Invest 2000; 19; 293-305
11. Nightingale CH. A survey of the quality of generic clarithromycin products manufactured in Slovenia and Israel. Adv Ther 2000; 17: 167-78
12. Morgan DK, Brown DM, Rotsch TD, et al. A reversed-phase high-performance liquid chromatographic method for the determination and identification of clarithromycin as the drug substance and in various dosage forms. J Pharm Biomed Anal 1991; 9: 261-9
13. Morgan DK, Cugier P, Marello B, et al. Impurity profiling of clarithromycin using high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1990; 502: 351-8
14. Davidson AG, McCallum A. A survey of the stability of omeprazole products from 13 countries. Drug Dev Ind Pharm 1996; 22: 1173-85
15. Ishii K, Katayama Y, Itai S, et al. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. Chem Pharm Bull 1995; 43: 1943-8
16. Qureshi SA, McGilveray IJ. Assessment of pharmaceutical quality of furosemide tablets from multinational markets. Drug Dev Ind Pharm 1998; 24: 995-1005
17. CPMP/ICH/282/95 Step 4, Consensus Guideline, 6 November 1996
18. USP 27, The United States Pharmacopeia, The United States Pharmacopeial Convention Inc., Rockville (MD), 2004